Target Postoperative Capillary Blood Glucose: ≤180 mg/dL
The target postoperative capillary blood glucose should be maintained at ≤180 mg/dL (≤10.0 mmol/L) using continuous intravenous insulin infusion to reduce adverse events including deep sternal wound infection, mortality, and other complications after surgery. 1, 2, 3, 1
Evidence-Based Target Range
The most recent and highest-quality guidelines consistently recommend:
- Primary target: <180 mg/dL for early postoperative period 1, 2, 3, 1
- Acceptable range: 100-180 mg/dL for perioperative period (within 4 hours of surgery) 4, 5
- Broader acceptable range: 140-180 mg/dL for most critically ill and non-critically ill patients 4
The 2023 AHA/ACC guidelines specifically state that patients with diabetes or stress hyperglycemia undergoing CABG should be treated with intravenous insulin infusion targeting blood glucose <180 mg/dL 3. This recommendation is based on Level B evidence showing reduced infection rates, shorter hospital stays, and improved survival when this target is maintained 3.
Why Not Tighter Control?
Stricter targets (<140 mg/dL intraoperatively) have uncertain effectiveness and are classified as Class IIb evidence 1, 2, 1. Multiple high-quality studies demonstrate:
- Targets of 80-110 mg/dL or 100-140 mg/dL showed no additional benefit over 120-180 mg/dL targets 6, 7
- Tighter control significantly increases hypoglycemia risk (10-15 fold higher rates) without improving outcomes 4
- The landmark NICE-SUGAR trial showed higher mortality with intensive glucose control 4
A 2012 prospective randomized trial in CABG patients definitively showed that liberal control (121-180 mg/dL) was non-inferior to strict control (90-120 mg/dL) for perioperative complications, but superior for glucose control with fewer hypoglycemic events 7.
Implementation Strategy
Use continuous intravenous insulin infusion starting in the operating room and continuing through the early postoperative period (typically first 72 hours or until stable oral intake) 1, 2, 3:
- Initiate insulin when blood glucose persistently >180 mg/dL 4
- Monitor capillary blood glucose every 2-4 hours minimum 4
- Maintain electronic insulin infusion until stable levels <180 mg/dL achieved 8
- Transition to subcutaneous basal insulin 2-4 hours before stopping IV insulin to prevent rebound hyperglycemia 5
Critical Pitfalls to Avoid
Do not pursue overly aggressive targets (<110 mg/dL or <140 mg/dL) as this increases hypoglycemia without improving outcomes 4, 7. The evidence clearly shows that:
- Blood glucose <100 mg/dL predicts hypoglycemia within 24 hours 4
- Severe hypoglycemia (<40 mg/dL) can occur with aggressive protocols 9
- Intraoperative glucose <140 mg/dL was not associated with improved outcomes compared to moderate hyperglycemia 2
Monitor for hypoglycemia aggressively: Any blood glucose <60 mg/dL requires immediate treatment, even without symptoms 8. Hypoglycemia unawareness is common in hospitalized patients 8.
Special Populations
For cardiac surgery patients specifically, the evidence is particularly robust for the ≤180 mg/dL target, with demonstrated reductions in:
- Deep sternal wound infections (2.0% to 0.8%) 3
- Atrial fibrillation rates 3
- Length of stay 3
- 2-year mortality 3
For non-cardiac surgery, the same 100-180 mg/dL perioperative target applies 4, 5, with basal-bolus insulin coverage superior to correction-only sliding scale approaches 4.